Trial ends in Request Full Access Tell Your Colleague About Jove

Methods Collections > Molecular imaging from bench to bedside in translational medicine  

Sergio Souza

Affiliation: School of Medicine of The Federal University of Rio de Janeiro

I have been working in the field of Nuclear medicine since the beginning of my career as a Scientist. I’ve been working with the development of new radiopharmaceuticals for more than 10 years. My master’s and doctorate thesis regarded the use of leukocytes labeled with Technetium-99m (Tc-99m) as a diagnostic radiopharmaceutical for differential diagnosis of acute tubular necrosis and renal allograft rejection and as a tool to identify the site of infection/inflammation in patients with fever of unknown origin. Since then, I’ve been using my expertise in radiolabeling to collaborate in some interesting pre-clinical research with stem cells, some of which advanced to clinical trials, and to develop new radiopharmaceuticals based mostly on antibodies and proteins, among them Ixolaris, anti-CD3, Doxorubicin and anti-TNF-alpha, some already in use at the clinical scenario for rheumatoid arthritis, breast cancer and Graves disease. As an Associate Professor of Nuclear Medicine of the School of Medicine of The Federal University of Rio de Janeiro my research interests are related to the development of new radiopharmaceuticals for diagnosis and therapy in Oncology, Rheumatology, Infectious disease and Stem cell therapy. For this I'm committed to pre-clinical and translational research. My experience with Ixolaris started back in 2011 when I began a collaboration for a master’s student that I mentored

Get cutting-edge science videos from JoVE sent straight to your inbox every month.

Waiting X
simple hit counter